Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Clinical trial supports autologous stem cell transplantion in HIV-associated lymphoma

Joseph Alvarnas • 5 Dec 2014
ASH 2014
Diffuse Large B-Cell Lymphoma HIV-Associated Lymphoma Hodgkin Lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Joseph Alvarnas (City of Hope National Medical Center, Duarte, CA) presents data from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial, which prospectively evaluated overall survival after autologous haematopoietic stem cell transplantation in patients with chemotherapy-sensitive, relapsed or refractory HIV-associated lymphoma, including diffuse large B-cell lymphoma, plasmablastic lymphoma, Burkitt/Burkitt-like lymphoma and Hodgkin lymphoma.

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
2:17
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
Michael Jain • 11 Sep 2026
Optimizing post-CAR-T monitoring and community delivery after liso-cel
1:04
Optimizing post-CAR-T monitoring and community delivery after liso-cel
Bradley Hunter • 21 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals